Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30942655 | 1.00 | PNMT (0.50) | PNMTADRA2AGRIN2BADRA2BADRA2C | |
| SCHEMBL8716290 | 0.94 | PNMT (0.50) | PNMTADRA2AGRIN2BADRA2BADRA2C | |
| SCHEMBL4551781 | 0.88 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29370265 | 0.88 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL2728205 | 0.88 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29507804 | 0.81 | DRD2 (0.59) | PNMTADRA2AGRIN2BADRA2BADRA2C | |
| SCHEMBL1953206 | 0.81 | DRD2 (0.59) | PNMTADRA2AGRIN2BADRA2BADRA2C | |
| SCHEMBL23196100 | 0.81 | PNMT (0.54) | PNMTADRA2AGRIN2BADRA2BADRA2C | |
| SCHEMBL3442261 | 0.81 | DRD2 (0.54) | PNMTADRA2AGRIN2BADRA2BADRA2C | |
| SCHEMBL17248039 | 0.80 | TDP1 (0.51) | PNMTADRA2AGRIN2BADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| EP-1051394-B1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6333337-B1 | THE TREATMENT OF CARDIAC ARRHYTHMIAS AND CELL PROLIFERATIVE DISORDERS ARE DESCRIBED. | ICAGEN, INC. | 2001-12-25 | — | — | US | disclosed |
| EP-1051394-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037607-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | PNMT 3069/4885ADRA2A 4235/4885GRIN2B 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.